226 articles
Sosimerasib
Sosimerasib, sold as Jilemei, is an oral small-molecule KRAS G12C inhibitor developed in China and conditionally approved in February 2026 for previously treated advanced non-small cell lung cancer.
Sotorasib
Sotorasib (Lumakras/Lumykras, AMG 510) is Amgen's oral, covalent KRAS G12C inhibitor; FDA-accelerated approved May 2021 for previously treated KRAS G12C-mutated NSCLC, first KRAS G12C targeted therapy, with a 2025 combination indication with panitumumab in colorectal cancer.
SPH6162
SPH6162 (SPH-6162) is a preclinical WEE1-inhibitor small-molecule antitumor drug developed by Shanghai Pharmaceuticals' Central Research Institute; in October 2021 its ex-China rights were licensed to HUYABIO International for up to US$292.5 million plus 3-6% royalties, SPH's first overseas license-out.
SPR2015
SPR2015 is SciBrunch Therapeutics' preclinical oral molecular glue KRAS G12D (ON) inhibitor, licensed worldwide to Merck in September 2026 for $400 million upfront ($2.13 billion total), with nanomolar potency and colorectal xenograft activity.
SPYK04
SPYK04 is Chugai-discovered oral RAF-MEK molecular glue, a MEK1/2 inhibitor for MAPK-altered solid tumors; Phase I NCT04511845 showed 8.7% ORR, and InxMed licensed it worldwide in 2026.
Sunvozertinib
Sunvozertinib (Zegfrovy, DZD9008, 舒沃哲) is Dizal's oral irreversible EGFR/HER2 kinase inhibitor for EGFR exon 20 insertion NSCLC, approved in China (2023) and by FDA (2025), with WU-KONG28 first-line phase III data.
Sutetinib
Sutetinib (苏特替尼), an oral EGFR-TKI by Teligene/Jiangsu Maidu with Suzhong Pharmaceutical for China, targets rare EGFR mutations L861Q, G719X, S768I in NSCLC; phase III, IIb ORR 70.8%.
SYH2039
SYH2039 (SYH-2039, BG-89894) is CSPC's AI-discovered, highly selective MAT2A inhibitor for MTAP-deleted solid tumors, licensed globally to BeiGene/BeOne in December 2024 for $150M upfront and in Phase 1 trials.
Tacabrutideg
Tacabrutideg (BGB-16673) is BeOne Medicines' oral BTK-targeted chimeric degradation activating compound (CDAC/PROTAC) degrading wild-type and mutant BTK via cereblon, in Phase 3 trials for R/R CLL/SLL with FDA Fast Track and EMA PRIME designations.
Tacedinaline
Tacedinaline (CI-994, acetyldinaline, GOE5549, PD 123654) is an orally bioavailable benzamide histone deacetylase inhibitor developed by Pfizer for lung and pancreatic cancer and myeloma; it reached phase III trials but was discontinued and never approved.
Tagraxofusp
Tagraxofusp (Elzonris, SL-401, DT388IL3) is a CD123-directed cytotoxin fusing interleukin-3 to truncated diphtheria toxin; first FDA-approved (2018) treatment for blastic plasmacytoid dendritic cell neoplasm, with capillary leak syndrome as its key toxicity.
Taletrectinib adipate (AB-106, DS-6051b)
Taletrectinib adipate (AB-106, DS-6051b; Dabole/达伯乐, Ibtrozi) is an oral, CNS-active, selective next-generation ROS1 TKI for ROS1-positive advanced NSCLC, approved in China (2024), the US (2025), and Japan (2025), with activity against the G2032R resistance mutation.
Targeted therapy
Targeted therapy is a class of cancer treatment where drugs target specific molecular proteins, such as mutated antigens, driving tumor growth without killing all rapidly dividing cells.
Tasquinimod
Tasquinimod (ABR-215050, TASQ) is an oral quinoline-3-carboxamide immunomodulator targeting S100A9 and HDAC4; phase III in prostate cancer improved PFS but not survival, and it is now in myelofibrosis trials.
Tazemetostat
Tazemetostat, sold as Tazverik, is a first-in-class, orally active inhibitor of the methyltransferase EZH2 approved in 2020 for epithelioid sarcoma and follicular lymphoma, withdrawn in 2026 over secondary blood cancers.
Tenalisib
Tenalisib (RP6530) is an oral dual PI3K delta/gamma and SIK3-pathway inhibitor by Rhizen Pharmaceuticals, investigated in T-cell lymphoma (ORR 46% monotherapy, 75% with romidepsin) and breast cancer, with FDA fast-track and orphan drug status for PTCL.
Tepotinib
Tepotinib (Tepmetko), an oral selective MET kinase inhibitor by EMD Serono, treats metastatic NSCLC with MET exon 14 skipping; FDA accelerated approval 2021, traditional approval 2024, based on the VISION trial.
Tinengotinib
Tinengotinib (TT-00420) is TransThera's oral multi-kinase inhibitor targeting Aurora A/B, JAK, FGFR, and VEGFR kinases, developed for FGFR inhibitor-resistant FGFR2-altered cholangiocarcinoma; NDA accepted by China's NMPA in December 2025.
Tipifarnib
Tipifarnib (R115777, Zarnestra), an oral farnesyltransferase inhibitor and the first FTI in clinical trials; never FDA approved, failed phase III AML, now developed for HRAS-mutant HNSCC.
Tivantinib
Tivantinib (ARQ 197), an oral non-ATP-competitive MET inhibitor later shown to act as a cytotoxic microtubule-targeting agent, failed its METIV-HCC and JET-HCC phase III trials in MET-high hepatocellular carcinoma and was discontinued in 2017.
Tivozanib
Tivozanib (Fotivda) is an oral VEGFR-1/2/3 tyrosine kinase inhibitor by AVEO; FDA approved 2021 for relapsed/refractory advanced renal cell carcinoma after two or more prior systemic therapies, dosed 1.34 mg daily 21 on/7 off.
Tovorafenib
Tovorafenib (OJEMDA, formerly DAY101/TAK-580/MLN2480) is an oral, CNS-penetrant type II pan-RAF kinase inhibitor approved by FDA in April 2024 for relapsed/refractory pediatric low-grade glioma with BRAF fusion/rearrangement or V600 mutation, dosed once weekly.
Tunlametinib (HL-085)
Tunlametinib (HL-085, Keluping, 妥拉美替尼) is a selective oral MEK1/2 inhibitor from Shanghai KeChow Pharma, conditionally approved in China in March 2024 as the first targeted drug for NRAS-mutant advanced melanoma after anti-PD-1/PD-L1 failure.
Tyrosine kinase inhibitor therapy
Tyrosine kinase inhibitor (TKI) therapy is targeted drug treatment with small molecules that block the ATP-binding site of tyrosine kinases, stopping the signaling cancer cells use to grow and survive.
UA022 (KRAS G12D inhibitor)
UA022 is a preclinical KRAS G12D inhibitor discovered by Chinese biotech 祐森健恒 and exclusively licensed worldwide to AstraZeneca in November 2023 for $24 million upfront plus up to $395 million in milestones.
Umbralisib
Umbralisib (Ukoniq), an oral dual PI3Kδ/CK1ε inhibitor by TG Therapeutics, won accelerated FDA approval in February 2021 for relapsed/refractory marginal zone and follicular lymphoma; approval was withdrawn May 31, 2022 over UNITY-CLL survival and safety concerns.
Unecritinib fumarate (TQ-B3101)
Unecritinib fumarate (TQ-B3101, Anboni, 富马酸安奈克替尼) is an oral ALK/ROS1/c-Met inhibitor approved in China April 2024 for ROS1-positive advanced NSCLC; phase II ORR 80.2%, median PFS 16.5 months.
Uproleselan
Uproleselan (GMI-1271) is a glycomimetic E-selectin antagonist tested with chemotherapy in acute myeloid leukemia; phase 3 trials in relapsed/refractory and older newly diagnosed AML missed their primary survival endpoints.
Vatalanib
Vatalanib (PTK787/ZK 222584, pynasunate) is an oral aminophthalazine VEGFR tyrosine kinase inhibitor, also blocking PDGFR-beta, c-Kit, and c-Fms; its phase III CONFIRM colorectal cancer trials missed their primary endpoints and it was never approved.
Veliparib
Veliparib (ABT-888) is AbbVie's investigational oral PARP-1/2 inhibitor for BRCA-mutated and HR-deficient cancers; unlike approved PARP inhibitors it mainly blocks catalytic activity, shows negligible PARP trapping, and remains unapproved despite phase 3 VELIA and BROCADE3 trials.